Francesco Bertolini

From Top Italian Scientists Wiki
Francesco Bertolini
September 8th, 1961, Milan, Italy
University of Milan
cancer genomics, stem cell transplantation, animal models of cancer, metronomic chemotherapy, anti-angiogenic and immune-therapy, blood transfusion.
Director of the Laboratory of Hematology/Oncology at the European Institute of Oncology in Milan[1]
Top Italian Scientist in Biomedical Sciences [2]

Francesco Bertolini born in Milan, Italy, Sept 8, 1961; Married with Laura, father of three sons.

Scopus Author ID: 7005152585

ORCID ID: 0000-0001-5660-3255

Researcher ID: FYO-1287-2022

Current position

Dr. Bertolini is currently the Director of the Laboratory of Hematology/Oncology at the European Institute of Oncology in Milan, the largest comprehensive cancer center in Italy.

He takes care of patients and leads research programs in hematology/oncology, angiogenesis, immunotherapy, stem cell biology and transplantation.

Dr. Bertolini has published original research papers in different cancer-related fields, namely blood transfusion, stem cell transplantation, animal models of cancer, metronomic chemotherapy, anti-angiogenic and immune-therapy over a period of more than thirty years, generating robust networks with the international experts in these fields. These achievements were obtained combining the lead of a translational research laboratory (including animal models) with diagnostic and clinical activities, including care of cancer patients affected by hematological malignancies.

Major research achievements

In the 1985-1995 decade Dr Bertolini has developed and published a novel procedure for the preparation and storage of platelet concentrates that is currently in use in most transfusion centres worldwide. In the same timeframe he was also instrumental in the development of blood filters able to reduce alloimmunization and transfusion reactions.

From 1990 to 1998 he pioneered the field of cord blood collection and transplant. He realized in Milan the first EU cord blood bank and the first Italian cord blood transplants in patients. He also published procedures for ex vivo stem cell expansion and the first EU pilot clinical trial in the field.

From 1998 onward, at the European Institute of Oncology, Dr Bertolini published seminal studies about the biology of circulating endothelial cells and their progenitors, the development of metronomic chemotherapy and of anti-angiogenic therapies of cancer, the role of adipose tissue progenitors in cancer development and progression, and the development of optimal combinatorial therapies including checkpoint inhibitors. His research has led to novel biomarkers and to clinical protocols involving anti-angiogenic drugs in cancer. Dr Bertolini has also pioneered studies on the use of NSG mice in preclinical models of hematological diseases and of several types of solid tumors.


1980: High School Degree (Liceo Classico), Milan

1986: MD degree summa cum laude, Medical School of the University of Milan.

1989: Post-doctoral specialization degree (Board) in Clinical and Laboratory Hematology, Medical School of the University of Milan.

1991-1993: PhD in Experimental Medicine (Hematology-Oncology), Medical School of the Universiteit van Amsterdam, Amsterdam, the Netherlands.

2006: Masterclass in Health Business Administration, University of Milan.


1981-1986: Medical student in the blood research section and in the laboratory of immunology at the Blood Transfusion and Transplant Immunology Institute (Centro Trasfusionale e di Immunologia dei Trapianti), of the Milan University Hospital (Ospedale Maggiore Policlinico).

1989-1990: Visiting Research Scientist, Cardeza Foundation for Hematological Research, Thomas Jefferson University, Philadelphia, USA. Laboratory of Scott Murphy, MD.

1989-1995: Medical assistant, Blood Transfusion and Transplant Immunology Institute, Department of Hematology, Ospedale Maggiore Policlinico, Milan. Since 1992, head of the stem cell laboratory devoted to stem cell collection from umbilical cord blood as part of the European Cord Blood Bank Project. Other fields of interests: cytokine-mediated mobilization of stem cells into peripheral blood, stem cell expansion and gene transfer into hematopoietic progenitor cells. Platelet transfusion, leuko-depletion of blood components.

1995-1998: Vice-Director and Head of the Experimental Hematology-Oncology Lab, Division of Medical Oncology, Scientific Institute (IRCCS) Maugeri Foundation, Pavia Medical Center, Pavia.

1998-onward: Director (formerly Vice-Director, 1998-2000, and Co-Director, 2001-2005) Division of Laboratory of Hematology-Oncology, IRCCS European Institute of Oncology, Milan.

2022-onward: PI at Onco-Tech Lab, European Institute of Oncology IRCCS and Politecnico di Milano, Milan, Italy

Current clinical interests: Diagnosis and treatment of hematological malignancies. Dr. Bertolini’s lab is in charge for the molecular (NGS, PCR, FISH, cytogenetic, etc) and cytometric diagnoses of myeloid and lymphoid malignancies at the European Institute of Oncology.

Current research intrests: Immunotherapy, in vitro and in vivo models of hematopoiesis, adipose progenitor cells and cancer, angiogenesis and angiogenesis inhibitors, preclinical animal models of neoplasia. Autologous and allogeneic transplantation of hematopoietic stem cells.


2022-onward: Adjunct Professor of Biological Sciences, College of Science, University of Texas at El Paso, USA.

2022-onward: PI at Onco-Tech Lab, European Institute of Oncology IRCCS and Politecnico di Milano, Milan, Italy

1992-96: Instructor of Laboratory Medicine at the University of Milan. 1992-onward: Teacher of the post-graduate Medical School of Oncology, Internal Medicine, Hematology and Radiololgy at the University of Milan. 2009-onward, teacher at the Advanced Breast Cancer Research Course, University of Milan. 2009-onward: teacher at the Faculty of Biology, University of Milan.

2008-onward: Faculty member, the European School of Molecular Medicine (SEMM, Milan) PhD program.

2013: Enabled as Associate Professor of Hematology-Oncology

2014: Enabled as Full (Ordinary) Professor of General and Clinical Pathology

2014: Enabled as Full (Ordinary) Professor of Medical Technologies

2017: Enabled as Full (Ordinary) Professor of Hematology-Oncology

2024: Member of Sigma Xi, The USA Scientific Research Honor Society

2020-onward: Evaluator of PhD candidates, University of Genoa.

Editorial, technical and ad hoc committees

2013-onward: Academic Editor, PLoS ONE

2020-onward: Editor, Cancers

2022-onward: Section Editor, Frontiers in Immunology

Member of the Editorial Board, PLoS ONE, Cancer Reports, Cancers, Frontiers in Oncology – Cancer Genetics, PeerJ, Ecancermedicalscience, Oncological Science, Clinical Cancer Drugs, European Journal of Clinical and Medical Oncology, Journal of Hematology and Hematotherapy.

Referee for Nature, Nature Biotechnology, Nature Communications, PNAS, Lancet Oncology, Journal of Clinical Investigation, Journal of the National Cancer Institute, Journal of Clinical Oncology, Nature Reviews in Clinical Oncology, Nature Reviews Gastroenterology and Hepatology , Nature Reviews Endocrinology, Blood, Cancer Research, Clinical Cancer Research, Cancer Immunology Research, BBA-Reviews on Cancer, Journal for ImmunoTherapy of Cancer, Oncogene, Molecular Cancer, Molecular Cancer Research, Cancers, Experimental Hematology, FASEB Journal, Annals of Oncology, Differentiation, Leukemia, Hepatology, Stem Cells, Annals of Oncology, Cancer Treatment Reviews, Cancer and Metastases Review, American Journal of Pathology, Theranostics, NPJ Breast cancer, Journal of Pathology, Oncotarget, PLOS ONE, EBioMedicine, Neoplasia, Cancer Prevention Research, Thrombosis and Haemostasis, International Journal of Cancer, Scientific Reports, European Journal of Cancer, British Journal of Cancer, Frontiers in Oncology, Frontiers in Immunology, British Medical Bulletin, Journal of Global Oncology, Cancer Letters, Carcinogenesis, Molecular Cancer, JCM, Medicinal Research Reviews, Journal of Cellular and Molecular Medicine, BMC Cancer, BMC Gastroenterology, British Journal of Haematology, Breast Cancer Research, Breast Cancer Research and Treatment, Angiogenesis, Microvascular Research, Communications Biology, Investigational New Drugs, Expert Opinion on Therapeutic Targets, Tumor Biology, Human Immunology, Cell Proliferation, Cancer Biology and Therapy, Molecular Cancer Research, International Journal of Molecular Science, Clinical and Experimental Medicine, Molecular Cancer, New Drugs and Perspectives, Investigational New Drugs, International Journal of Medical Science, Hematological Oncology, Journal of Cancer Research and Clinical Oncology, European Journal of Hematology, Annals of Hematology, Advances in Hematology, European Journal of Internal Medicine, Future Oncology; Drug Design, Development and Therapy; European Journal of Cancer Prevention, Journal of Laboratory and Clinical Medicine, Biomedicines, Molecules, Neurosurgery, Vox Sanguinins, Haematologica, Journal of Cellular Physiology, Advances in Therapy, European Journal of Obstetrics & Gynecology and Reproductive Biology, Therapeutic Advances in Medical Oncology, Drug Design, Development and Therapy.

Abstract reviewer for the meetings of the American Society of Hematology (2005) and the European Hematology Association (2008).

Reviewer for the European Research Counsil (ERC), the European Commission in the 6th and 7th Framework Programmes, the Worldwide Cancer Research, Health Research Board of the republic of Ireland, the Israeli Ministry of Innovation, Science and Technology, the Israel Science Foundation, the German-Israeli Foundation and for the University of Vienna.

Consultant of the the Spanish Ministry of Health and Consumer's Affairs in the national programme of cooperative research aiming to integrate research from basic and clinical groups.

Consultant of the French national Cancer Institute for the review of grant applications.

Consultant of the Polish national Cancer Institute for the review of grant applications.

Consultant of the Swiss Cancer Ligue for the review of grant applications.

Consultant of the Swiss National Science Foundation for the review of grant applications.

Consultant of the Dutch Cancer Society for the review of grant applications.

Consultant of the Irish Research Council for the review of grant applications

Consultant of the Austrian Science Fund for the review of grant applications

2011-onward: Member of the Health Technology Assessment Board of Regione Lombardia (Lombardy section of the Italian National Health System)

2016-onward: Member of the SAB, BiovelocITA (institutional incubator for Italian biotech companies).

Consultant for hematopoietic stem cell transplant for the Italian National Institute of Health.

Since 1996: Scholar of the National Blood Foundation of the American Association of Blood Banks.

Member of the Board: European Union Concerted Action Eurocord, Immunobiology Working Party of the EBMT (European Group for Blood and Marrow Transplantation), European School of Transfusion Medicine, Cord Blood Committee of the International Society of Hematotherapy and Graft Engeneering (ISHAGE), European Cord Blood Bank.

Full member: International Society of Experimental Hematology (ISEH), American Society of Hematology (ASH), American Association for Cancer Research (AACR), European Assiciation for cancer Research (EACR), American Society of Gene Transfer (ASGT), International Society of Cell Therapy (ISCT, formerly International Society of Hematotherapy and Graft Engeneering, ISHAGE), American Association of Blood Banks (AABB), American Association for the Advancement of Science (AAAS), European Working Group on Human Gene Transfer (EWGT), European Union Concerted Action on Hematopoietic Stem Cells, Italian group for the study of bone marrow transplantation (GITMO).

Awards: Corriere della Sera “Gli Italiani che cambiano l’Italia” Award (2009). Marangoni Award of the Maggiore Hospital of Milan for scientific merit (1986). The abstract "In vitro and in vivo evaluation of the hematopoietic potential of human muscle cells." has been awarded as the best 2001 scientific presentation either at the European Hematology Association (EHA) meeting in Frankfurt and at the Italian Society of Hematology (SIE) meeting in Florence.

Grants (>8.5m € total)

Dr. Bertolini received a total of >8.5 million € grants from Institutions as EU, the US National Blood Foundation, Italian Ministry of Health, AIRC, Istituto Superiore di Sanità, Alleanza contro il Cancro, Fondazione Umberto Veronesi, Regione Lombardia, and from Pharma Companies.

Doctoral and post-doctoral students- trainees

42 in total (12 become independent scientists), including 4 PhD thesis supervision and 2 PhD Thesis at SEMM.

Peer reviewed papers

As of Jan 1st, 2024, dr. Bertolini has >270 full papers, >21,080 citations (Google Scholar; Scopus >12,320 citations), h-index 76 (Google Scholar; Web of Science h-index 60; Scopus h-index 60). One paper (FB first author) has >700 citations, 2 papers (FB first author) have >600 citations, 5 papers (3 of them with FB first or last author) has >500 citations, 7 papers (FB first or last author in 4 of 7) has >400 citations, 23 papers (9 out of 23 with FB first or senior author) have >200 citations (Google Scholar).

Included in the 2021 and 2022 “top 2% science-wide author databases of standardized citation indicators” of Stanford University in 2022 and 2023.

Sirchia G, Parravicini A, Rebulla P, Bertolini F, Morelati F, Marconi M. Preparation of leukocyte-free platelets for transfusion through cotton wool. Vox Sang 1983;44:115-120.

Sirchia G, Rebulla P, Parravicini A, Carnelli V, Gianotti GA, Bertolini F. Leukocyte depletion of red cells units at the bedside by transfusion through Sepacell R-500. Transfusion 1987;27:402-405.

Rebulla P, Baroni L, Bertolini F, Sirchia G. The risk of acquiring transfusion-transmissible infections (letter). Vox Sang 1988;55:186-187.

Bertolini F, Rebulla P, Riccardi D, Cortellaro M, Ranzi ML, Sirchia G. Evaluation of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. Transfusion 1989;29:605-609.

Sirchia G, Wenz B, Rebulla P, Parravicini A, Carnelli V, Bertolini F. Removal of white cells from red cells by transfusion through a new filter. Transfusion 1990:30:30-33.

Rebulla P, Bertolini F for the Cooleycare cooperative group. Transfusion reactions in thalassemia. A survey from the Cooleycare programme. Haematologica 1990;75:122-125.

Rebulla P, Bertolini F, Riccardi D, Smacchia C, Sirchia G. Platelet concentrates prepared from pooled buffy coats and stored in a glucose-free crystalloid medium. The Milan experience. Transfus Sci 1990;11:357-362.

Rebulla P, Bertolini F, Parravicini A, Sirchia G. Leukocyte-poor blood components: purer and safer transfusion for all recipients? Transf Med Rev 1990;4 (suppl 1):19-23.

Rebulla P, Modell B and the Cooleycare study group (including Bertolini F). Transfusion requirements and effects in patients with thalassemia major. Lancet 1991;337:277-280.

Bertolini F, Rebulla P, Porretti L, Sirchia G. Comparison of platelet activation and membrane glycoprotein Ib and IIb-IIIa expression after filtration through three different leukocyte removal filters. Vox Sang 1990;59:201-204.

Bertolini F, Rebulla P, Porretti L, Murphy S. Platelet quality after 15-day storage of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. Transfusion 1992;32:9-16.

Bertolini F, Murphy S, Rebulla P, Sirchia G. Role of acetate during platelet storage in a synthetic medium. Transfusion 1992;32:152-156.

Bertolini F, Rebulla P, Marangoni F, Sirchia G. Platelet concentrates stored in synthetic medium after filtration. Vox Sang 1992;62:82-86.

Rebulla P, Porretti L, Bertolini F, Marangoni F, Prati D, Smacchia C, Pappalettera M, Parravicini A, Sirchia G. White cell reduced red blood cells prepared by filtration: a critical evaluation of current filters and methods for counting residual white cells. Transfusion 1993;33:128-133.

Bertolini F, Porretti L, Corsini C, Rebulla P, Sirchia G. Platelet quality and reduction of HLA expression in acid-treated platelet concentrates (letter). Br J Haematol 1993;83:525-527.

Rebulla P, Bertolini F, Porretti L, Marangoni F, Smacchia C, Marconi M, Riccardi D, Sirelson V, Pappalettera M, Sirchia G. Platelet concentrates from buffy coats: improved conditions for preparation and evaluation in routine clinical use. Transfus Sci 1993;14:41-46.

Bertolini F, Porretti L, Lauri E, Rebulla P, Sirchia G. Role of lactate in platelet storage lesion. Vox Sang 1993;65:194-198.

Murphy S, Rebulla P, Bertolini F, Holme S, Moroff G, Snyder E, Stromberg R for the BEST (Biomedical Excellence for Safer Transfusion) Task Force of the International Society of Blood Transfusion. In vitro assessment of the quality of platelet concentrates. Transf Med Rev 1994;8:29-36.

Bertolini F, Marangoni F, Loy A, Marconi M, Almini D, Rebulla P, Sirchia G. Single-donor platelet concentrates stored in synthetic medium: In vitro and in vivo studies. Int J Art Org 1993, 16 (suppl. 5): 135-138.

Bertolini F, Corsini C, Lauri E, Gorini F, Sirchia G. Cord blood banking: evaluation of the collection procedure and of CFU-GM content. J Hematother 1993, 2: 233-234.

Bertolini F, Lazzari L, Corsini C, Lauri E, Gorini F, Sirchia G. Cord blood banking for stem cell transplant. Int J Art Org 1993; 16 (suppl. 5): 111-112.

Bertolini F and Murphy S for the BEST Working Party of the ISBT. A multicenter evaluation of reproducibility of swirling in platelet concentrates. Transfusion 1994;34:796-801.

Bertolini F, Lazzari L, Corsini C, Lauri E, Sirchia G. Cord blood plasma-mediated ex-vivo expansion of hematopoietic progenitor cells. Bone Marrow Transplant 1994;14:347-353.

Bertolini F, De Monte L, Corsini C, Lazzari L, Lauri E, Soligo D, Ward M, Bank A, Malavasi F. Retrovirus-mediated transfer of the multidrug resistance gene into human haematopoietic progenitor cells. Br J Haematol 1994;88:318-324.

Bertolini F, Lazzari L, Corsini C, Lauri E, Castelli C, Gorini F, Sirchia G. A comparative study of different procedures for the collection and banking of umbilical cord blood. J Hematother 1995;4:29-36.

Bertolini F, Lazzari L, Corsini C, Lauri E, Sirchia G. Cord blood-derived hematopoietic progenitors retain their potential for ex-vivo expansion after cryopreservation (letter). Bone Marrow Transplant 1995;15:159-160.

Rawal B, Bertolini F, Vyas G. In vitro inactivation of HIV by ascorbic acid. Biologicals 1995;23:75-81.

Bertolini F, Soligo D, Lazzari L, Corsini C, Servida F, Sirchia G. The effect of interkleukin 12 in ex-vivo expansion of human hematopoietic progenitors. Br J Haematol, 1995;90:935-938.

Bertolini F, Rosti L, Battaglia M, De Iulio C, Sirchia G. Placental blood collection: Effects on the newborns. Blood 1995;85:3361-3362.

Bertolini F, Corsini C, Lazzari L, Soligo D, De Monte L, Ward M, Bank A, Sirchia G. Gene transfer-mediated generation of drug-resistant hemopoiesis (review). Leuk Lymphoma 1996;18:179-184.

Dallorso S, Dufour C, Bertolini F, Dini G, Sirchia G, Mori PG. Combined transplantation with related HLA-identical cord blood and bone marrow in a child with severe acquired aplastic anaemia (letter). Eur J Haematol 1996;56:256-258.

Servida F, Soligo D, Caneva L, Bertolini F, Campiglio S, de Harven E, Corsini C, Lambertenghi-Deliliers G. Functional and morphological characterization of immunomagnetically selected CD34+ hematopoietic progenitor cells. Stem Cells 1996;14:430-438.

Pedrazzoli P, Gibelli N, Pavesi L, Preti P, Piolini M, Bertolini F, Robustelli della Cuna G. Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. Anticancer Res 1996;16:1781-1786.

Lambertenghi-Deliliers G, Soligo D, Della Volpe A, Bertolini F, Poli F, Romitti L, Tagliaferri E, Ibatici A, Onida F, Annaloro C, Gattinoni L, Sirchia G. Unrelated mismatched cord blood transplantation in an adult patient with secondary AML. Bone Marrow Transplant 1996;18:469-472.

Bertolini F, Murphy S for the BEST Working Party of the ISBT. A multicenter inspection of the swirling phenomenon in platelet concentrates prepared in routine practice. Transfusion 1996;36:128-132.

Bertolini F, Battaglia M, Corsini C, Lazzari L, Soligo D, Zibera C, Thalmeier K. Engineered stromal layers and continuous flow culture enhance multidrug resistance gene transfer in hematopoietic progenitors. Cancer Research 1996;56:2566-2572.

Bertolini F, Battaglia M, Zibera C, Baroni G, Soro V, Perotti C, Salvaneschi L, Robustelli della Cuna G. A new method for placental/cord blood processing in the collection bag. (i) Analysis of factors involved in red cell removal. Bone Marrow Transplant 1996;18:783-786.

Locatelli F, Maccario R, Comoli P, Bertolini F, Giorgiani G, Montagna D, Bonetti F, De Stefano P, Sirchia G, Severi F. Hematopoietic and immune recovery after transplantation of cord blood progenitor cells in children. Bone Marrow Transpl 1996;18:1095-1102

Bertolini F, Soligo D, Lazzari L, Corsini C, Battaglia M, Curioni C, Pedrazzoli P, Thalmeier K. "Stem cell candidates” purified by liquid culture in the presence of SCF, IL-3 and 5FU are strictly stroma-dependent and have myeloid, lymphoid and megakaryocytic potential. Exp Hematol 1997;25:350-356.

Pedrazzoli P, Perotti C, Da Prada GA, Bertolini F, Gibelli N, Torretta L, Battaglia M, Pavesi L, Preti P, Robustelli della Cuna G. Collection of peripheral blood progenitor cells after epirubicin, paclitaxel and recombinant G-CSF in patients with metastatic breast cancer. Br J Cancer 1997;75:1368-1372.

Bertolini F, Thomas T, Battaglia M, Gibelli N, Pedrazzoli P, Robustelli della Cuna G. A new “two step” procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation. Bone Marrow Transpl 1997;19:615-619

Bertolini F, Battaglia M, Pedrazzoli P, Da Prada GA, Lanza A, Soligo D, Caneva L, Sarina B, Murphy S, Thomas T, Robustelli della Cuna G. Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood 1997;89:2679-2688.

Bertolini F, De Vincentiis A, Lanata L, Lemoli RM, Majolino I, Ponchio L, Rondelli D, Tabilio A, Zanon P, Tura S. Allogeneic hematopoietic stem cells from sources other than bone marrow: biological and technical aspects. Haematologica 1997;82:220-238

Bertolini F, Robustelli della Cuna G. Placental-blood transplantation (letter). New Engl J Med 1997;336:68-70.

Pedrazzoli P, Battaglia M, Da Prada GA, Lanza A, Cuomo A, Bertolini F, Pavesi L, Robustelli della Cuna G. Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy. Bone Marrow Transpl 1997;20:167-169.

Bertolini F, Battaglia M, Lanza A, Gibelli N, Palermo B, Pavesi L, Caprotti M, Robustelli della Cuna G. Multilineage long-term engraftment potential of drug-resistant hematopoietic progenitors. Blood 1997;90:3027-3036.

Bertolini F, Battaglia M, Lanza A, Palermo B, Cuomo A, Preti P, Robustelli della Cuna G. Hematopoietic stem cells from different sources: biological and technical aspects. Bone Marrow Transpl 1998;21(suppl 2)S5-7.

Bertolini F, Gibelli N, Lanza A, Cuomo A, Robustelli della Cuna G, Nelson EJ. Effects of storage temperature and time on cord blood progenitor cells. Transfusion 1998;38:615-617.

Bertolini F, Lanza A, Peccatori F, Zibera C, Gibelli N, Perotti C, Da Prada GA, Torretta L, Cocorocchio E, Martinelli G, Robustelli della Cuna G. Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization. Ann Oncol 1998;9:913-916.

Battaglia M, Pedrazzoli P, Palermo B, Lanza A, Bertolini F, Gibelli N, Da Prada GA, Zambelli A, Perotti C, Robustelli della Cuna G. Epithelial tumor cell detection and the unsolved problems of nested RT-PCR. A new sensitive one step method without false positive results. Bone Marrow Transpl 1998;22:693-8.

Aglietta M, Bertolini F*, Carlo-Stella C, De Vincentiis A, Lanata L, Lemoli RM, Olivieri A, Siena S, Zanon P, Tura S. Ex vivo expansion of hematopoietic cells and their clinical use. Haematologica 1998;83:824-848.

Bertolini F, Battaglia M, Lanza A, Gibelli N, Palermo B, Pavesi L, Robustelli della Cuna G. Stem cell enumeration in cord blood vs bone marrow and peripheral blood. Bone Marrow Transpl 1998;22(suppl 1) s57

Bertolini F, Battaglia M, Lanza A, Palermo B, Robustelli della Cuna G. Control of stem cell proliferation and differentiation to achieve stable gene transfer and expression. Bone Marrow Transpl 1998;21(suppl 3) s75-76

Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G. Angiogenic growth factors and endostatin in non-Hodgkin’s lymphoma. Br J Haematol 1999; 106:504-9.

Pruneri G, Bertolini F*, Soligo D, Carboni N, Cortelezzi A, Buffa G, Lambertenghi-Deliliers G, Pezzella F. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999; 81:1398-1401.

Bertolini F, Agazzi A, Peccatori F, Martinelli G, Sandri MT. The absence of swirling in platelet concentrates is highly predictive of poor post-transfusion platelet increment and increased risk of transfusion reactions. Transfusion 2000;40:121-122.

Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G. Angiogenic growth factors and endostatin in non-Hodgkin’s lymphoma (Reply to the letter from Gunsilius et al). Br J Haematol 2000; 108:662-663.

Fusetti L, Gobbi A, Rabascio C, Pruneri G, Carboni N, Peccatori F, Martinelli G, Bertolini F. Human Myeloid and Lymphoid Malignancies in the Non-Obese Diabetic/Severe Combined Immunodeficiency Mouse Model: Frequency of Apoptotic Cells in Solid Tumors and Efficiency and Speed of Engraftment Correlate with Vascular Endothelial Growth Factor Production. Cancer Res 2000;60:2527-2534.

Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferrucci PF, Martinelli G, Pruneri G. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin's lymphoma. Blood 2000;96:282-287.

Bertolini F, Fusetti L, Rabascio C, Cinieri S, Martinelli G, Pruneri G. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in

animal models of human high-grade non-Hodgkin's lymphoma. Leukemia 2000;14:1477-82.

Bertolini F, Mancuso P, Gobbi A, Pruneri G. The thin red line: Angiogenesis in normal and malignant hematopoiesis (review). Exp Hematol 2000;28:993-1000.

Pignataro L, Carboni N, Midolo V, Bertolini F, Buffa R, Cesana BM, Neri A, Viale G, Pruneri G. The clinical relevance of microvessel density in laryngeal squamous cell carcinomas. Int J Cancer 2001;92:666-70.

Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-3661.

Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, Martinelli G, Bertolini F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001;61:4341-4.

Bertolini F, Mingrone W, Alietti A, Ferrucci PF, Cocorocchio E, Peccatori F, Cineri S, Mancuso P, Corsini C, Burlini A, Zucca E, Martinelli G. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol 2001;12: 987-990.

Bertolini F, Martinelli G, Goldhirsch A. High-dose chemotherapy for breast cancer: The relevance of mosaic tumor blood vessels (letter). The Lancet Oncology 2001;2:596.

Corsini C, Bertolini F*, Mancuso P, Cinieri S, Peccatori F, Martinelli G. Short- and long-term safety of the 2x106 CD34+ cells/Kg threshold for hematopoietic reconstitution after high-dose chemotherapy and peripheral blood progenitor cell support. Ann Oncol 2002;13: 983-5.

Dell'Agnola C, Rabascio C, Mancuso P, Capillo M, Pruneri G, Gobbi A, Minucci S, Ronzoni S, Volorio S, Calabrese L, Tradati N, Martinelli G, Shultz L, Bertolini F. In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue. Exp Hematol 2002;30:905-14.

Bertolini F, Dell'Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli, Gobbi A, Pruneri G, Martinelli G. CXCR4-neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002;62:3106-12.

Bertolini F, Pruneri G. Chimerism of the transplanted heart (letter). New Engl J Med 2002;346,1410-2.

Pruneri G, Ponzoni M, Ferreri AJM, Decarli N, Tresoldi M, Raggi F, Baldessari C, Freschi M, Baldini L, Goldaniga M, Neri A, Carboni N, Bertolini F, Viale G. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 2002;118:817-820.

Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchiano A, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G. Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings. J Clin Oncol 2002;20:4169-4180.

Martinelli G, Agazzi A, Laszlo D, Santoro P, Mancuso P, Prineri G, Greco P, Bertolini F. Idarubicin containing regimen in multiple myeloma: Preliminary results of a pilot study using a modified "tandem" transplant program. Leuk Lymphoma 2003;44:299-302.

Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, Dell'Agnola C, Martinelli G, Shultz L, Bertolini F.Continuous infusion of endostatin inhibits differentiation, mobilization and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 2003;9:377-382.

Pruneri G, Bertolini F, Baldini L, Valentini S, Goldaniga M, Soligo D, Carboni N, Viale G, Lambertenghi Deliliers G. Angiogenesis occurs in hairy cell leukemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. Br J Haematol 2003;120:695-698.

Pruneri G, Carboni N, Baldini L, Intini D, Colombi M, Bertolini F, Valentini S, Maisonneuve P, Viale G, Neri A. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. Hum Pathol 2003;34:41-7.

Corsini C, Mancuso P, Paul S, Burlini A, Martineli G, Pruneri G, Bertolini F. Stroma cells: a novel target of Herceptin activity. Clin Cancer Res 2003;9:1820-5.

Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-6.

Pruneri G, Mazzarol G, Fabris S, Del Curto B, Bertolini F, Neri A, Viale G. Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation. Mod Pathol 2003;16:886-92.

Martinelli G, Laszlo D, Bertolini F, Pastano R, Mancuso P, Calleri A, Vanazzi A, Santoro P, Cavalli F, Zucca E. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Haematol 2003; 123:271-7.

Lemoli RM, Bertolini F, Petrucci MT, Gregorj C, Ricciardi MR, Fogli M, Curti A, Rabascio C, Pandolfi S, Ferrari S, Foa R, Baccarani M, Tafuri A. Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34- human stem cells. Br J Haematol 2003; 123:720-9.

Bertoni F, Conconi A, Cogliatti SB, Schmitz SF, Ghielmini M, Cerny T, Fey M, Pichert G, Bertolini F, Ponzoni M, Baldini L, Jones C, Auer R, Zucca E, Cavalli F, Cotter FE. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. Br J Haematol 2004; 124:289-98.

Bertolini F. AGF will make you blush (commentary). Blood 2004;103:3610-1.

Bossolasco P, Corti S, Strazzer S, Borsotti C, Del Bo R, Fortunato F, Salani S, Quirici N, Bertolini F, Gobbi A, Lambertenghi-Deliliers G, Comi GP, Soligo D. Skeletal muscle differentiation potential of human adult bone marrow cells. Exp Cell Res, 2004;295:66-78.

Pruneri G, Valentini S, Fabris S, Del Curto B, Laszlo D, Bertolini F, Martinelli G, Leocata P, Viale G, Neri A. Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labelling index. Int J Cancer 2004;112:71-7.

Rabascio C, Muratori E, Mancuso P, Calleri A, Raia V, Foutz T, Cinieri S, Veronesi G, Pruneri G, Lampertico P, Iavarone M, Martinelli G, Goldhirsch A, Bertolini F. Assessing tumor angiogenesis: Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res, 2004;64:4373-7.

Lemoli RM, Ferrari D, Fogli M, Rossi L, Pizzirani C, Forchap S, Chiozzi P, Vaselli D, Bertolini F, Foutz T, Aluigi M, Baccarani M, Di Virgilio F. Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. Blood 2004;104:1662-70.

Ponzoni M, Savage DG, Ferreri JM, Pruneri G, Viale G, Servida P, Bertolini F, Orazi A. Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. Mod Pathol 2004;17:1513-20.

Ferrucci PF, Rabascio C, Mazzetta C, Cocorocchio E, Agazzi A, Vanazzi A, Cinieri S,

Peccatori F, Paolucci M, Bertolini F, Martinelli G. Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer. Clin Cancer Res 2004; 10:6039-46.

Pompilio G, Cannata A, Peccatori F, Bertolini F, Nascimbene A, Capogrossi MC, Biglioli P. Autologous peripheral blood stem cell transplantation for myocardial regeneration: a novel strategy for cell collection and surgical injection. Ann Thorac Surg. 2004;78:1808-12.

Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D’Amato RJ, Kerbel RS. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate markers and analysis of antiangiogenesis. Cancer Cell 2005;7:101-11.

Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, Haubitz M, Hebbel RP, Lip GY, Mancuso P, Sampol J, Solovey A, Dignat-George F. Circulating endothelial cells. Biomarker of vascular disease (review). Thromb Haemost. 2005;93:228-35.

Lemoli RM, Bertolini F*, Cancedda R, De Luca M, Del santo A, Ferrari G, Ferrari S, Martino G, Mavilio F, Tura S. Stem cell plasticity: Time for a reappraisal? (Review) Haematologica/The Hematology Journal 2005;90:360-81.

Bertolini F. Targeting VE-cadherin (while naked, and not engaged) (commentary). Blood 2005;105:4157.

Pruneri G, Fabris S, Dell'orto P, Biasi MO, Valentini S, Del Curto B, Laszlo D, Cattaneo L, Fasani R, Rossini L, Manzotti M, Bertolini F, Martinelli G, Neri A, Viale G. The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J Pathol 2005;206:337-45.

Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben David Y, Kerbel RS. The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-61.

Shaked Y, Bocci G, Munoz R, Man S, Ebos JML, Hicklin DJ, Bertolini F, D’Amato R, Kerbel RS. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Target 2005;5:551-9.

Curigliano G, Petit Y, Bertolini F, Colleoni M, Peruzzotti G, De Braud F, Orlando L, Munzone E, Luini A, Goldhirsch A. Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF-beta) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery. Breast Cancer Res Treat. 2005;93:35-40

Pruneri G, Valentini S, Bertolini F, Del Curto B, Maiorano E, Viale G. SP4, a Novel Anti-CyclinD1Rabbit Monoclonal Antibody, Is a Highly Sensitive Probe for Identifying Mantle Cell LymphomasBearing the t(11;14)(q13;q32) Translocation. Appl Immunohistochem Mol Morphol 2005;13:318-22.

Bertolini F ,Mancuso P, Kerbel RS. Endothelial progenitor cells (letter). New England Journal of Medicine 2005;353:2613-6.

Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-9.

Pruneri G, Ponzoni M, Ferreri AJ, Freschi M, Tresoldi M, Baldini L, Mattioli M, Agnelli L, Govi S, Agazzi A, Mancuso P, Bertolini F, Peccatori J, Bosari S, Granelli U, Viale G, Neri A. The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology 2006; 48:529-35.

Shaked Y, Bertolini F, Emmenegger U, Lee CR, Kerbel RS. On the origin and nature of elevated levels of circulating endothelial cells (CECs) after treatment with a vascular disrupting agent (letter). J Clin Oncol 2006;24:4040.

Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M. High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed

and Refractory Aggressive Histology Non-Hodgkin's Lymphoma. Clin Cancer Res 2006;12 5190-8.

Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: from promiscuity to surrogate marker and target identification. Nature Reviews Cancer 2006;6:835-45.

Rossi L, Manfredini R, Bertolini F, Ferrari D, Fogli M, Zini R, Salati S, Salvestrini V, Mulinelli S, Adinolfi E, Ferrari S, Di Virgilio F, Baccarani M, Lemoli RM. The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. Blood 2007;109:533-542.

Iavarone M, Lampertico P, Iannuzzi F, Manenti E, Donato MF, Arosio E, Bertolini F, Primigiani M, Sangiovanni A, Colombo M. Increased expression of VEGF in small hepatocellular carcinoma. J Virol Hepat 2007;14:133-139.

Bordoni V, Alonzi T, Zanetta L, Khouri D, Conti A, Corazzari M, Bertolini F, Antoniotti P, Pisani G, Tognoli F, Dejana E, Tripodi M. Hepatocyte-conditioned medium sustains endothelial differentiation of human hematopoietic-endothelial progenitors. Hepatology 2007;45:1218-1228.

Bertolini F, Mancuso P, Shaked Y, Kerbel RS. Molecular and cellular biomarkers for angiogenesis in oncology. Drug Discovery Today 2007;12:806-12.

Bertolini F. Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells. Cancer Metastasis Review, 2008:27:95-101.

Li H, Raia V, Bertolini F, Price DK, Figg WD. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU International 2008;101:884-8.

Mancuso P, Peccatori F, Roca A, Talleri A, Antoniotti P, Rabascio C, Saronni L, Zorzino L, Sandri MT, Cubani A, Bertolini F. Circulating endothelial cell number and viability

are reduced by exposure to high altitude. Endothelium 2008;15:53-58.

Agliano A, Martin-Padura I, Marighetti P, Mancuso P, Rabascio C, Pruneri G, Shultz LD, Bertolini F. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 2008;123:2222-7.

Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer: clinical and biological activity. J Clin Oncol, 2008;26:4899-905.

Kerbel RS, Benezra R, Lyden DC, Hattori K, Heissig B, Nolan D, Mittal V, Bertolini F*, Rafii S. Endothelial progenitors are cellular hubs essential for neo-angiogenesis of certain aggressive tumors and metastatic transition. Proceeedings of the National Academy of Science USA, 2008, DOI 10.1073_pnas.0804876105

Shaked Y, Henke E, Roodhart J, Mancuso P, Langenberg M, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest E, Benezra R, Kerbel RS. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell, 2008;14:263-1273.

Torrisi R, Bagnardi V, Cardillo A, Bertolini F, Scarano E, Orlando L, Mancuso P, Luini A, Calleri A, Viale G, Goldhirsch A, Colleoni M. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 2008;99:1564-71.

Martin-Padura I, Bertolini F. The circulating endothelial cell in cancer: towards marker and target identification. Curr Pharm Des 2008; 14:378-9.

Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu H, Zurida AJ, Saronni L, Cheng JB, Shalinsky DR, Heymach JV, Bertolini F. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry, molecular and ultrastructural analyses. Clinical Cancer Research, 2009;15:267-73.

Biguzzi E, Mancuso P, Franchi F, Calleri A, Mancuso ME, Santagostino E, Bucciarelli P, Bertolini F, Mannucci PM. Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype. Br J Haematol, 2009;144:803-5.

Balduzzi A, Montagna E, Bagnardi V, Torrisi R, Bertolini F, Mancuso P, Scarano E, Viale G, Veronesi P, Cardillo A, Orlando L, Goldhirsch A, Colleoni M. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anticancer Drugs, 2009;20:197-203.

Bertolini F, Mancuso P, Braidotti P, Shaked Y, Kerbel RS. The multiple personality disorder phenotyope(s) of circulating endothelial cells in cancer. Biochim Biophys Acta Reviews Cancer 2009;1796:27-32.

Mancuso P, Calleri A, Bertolini F, Tacchetti C, Heymach JV, Shalinsky DR. Quantification of Circulating Endothelial Cells by Flow Cytometry. Clin Cancer Res 2009;15 3640

Martin-Padura I, Bertolini F. Circulating endothelial cells as biomarkers for angiogenesis in tumor progression. Front Biosci (Schol Ed) 2009;1:304-318.

Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, Cai S, Armeit JM, Voest EE, Chaplin D, Smythe J, Harris A, Nathan P, Judson I, Rustin G, Bertolini F, Link DC, Kerbel RS. Contribution of G-CSF to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Research 2009;69:7524-8.

Bertolini F. Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology. Breast 2009;18S3:S48-50.

Lemoli RM, Salvestrini V, Bianchi E, Bertolini F, Fogli M, Amabile M, Tafuri A, Salati S, Zini R, Testoni N, Rabascio C, Rossi L, Martin Padura I, Castagnetti F, Marighetti P, Martinelli G,

Baccarani M, Ferrari S, Manfredini R. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood 2009;114:5191-200.

Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, Colleoni M, Bertolini F. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 2009;15:7652-7.

Rabascio C, Laszlo D, Andreola G, Saronni L, Radice D, Rigacci L, Fabbri A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. Leukemia Research, 2010;34:454-7.

Porretti L, Cattaneo A, Colombo F, Lopa R, Rossi G, Mazzaferro V, Battiston C, Svegliati-Baroni G, Bertolini F, Rebulla P, Prati D. Simultaneous characterization of progenitor cell compartments in adult human liver. Cytometry part A, 2010;77A:31-40.

Noberasco C, Spitaleri G, Mancuso P, Zorzino L, Radice D, Milani A, Rocca A, Bertolini F, Sandri MT, Curigliano G, de Pas T, Jemos C, Omodeo Salè E, Boselli S, de Braud F. Safety, Tolerability and Biological Effects of Long-Term Metronomic Administration of Non-Cytotoxic Anti-Angiogenic Agents. Oncology 2010;77:358-65

Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, Pruneri G, Radice D, Pinto A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G. Rituximab And Subcutaneous 2-Chloro-2'-Deoxyadenosine (2-CdA) Combination Treatment For Patients With Waldenstrom’s Macroglobulinemia (WM): Clinical And Biological Results Of A Phase II Multicenter Study. J Clin Oncol 2010;28:2233-8

Lapucci A, Lulli M, Amedei A, Papucci L, Withold E, di Gesualdo F, Bertolini F, Brewer G, Nicolin A, Bevilacqua A, Schiavone N, Morello D, Donnini M, Capaccioli S. Z-cristallin is a bcl-2 mRNA bindingprotein involved in bcl-2 overexpression in T-cell acute lymphoblastic leukemia. FASEB J, 2010;24:1852-65.

Mancuso P, Bertolini F. Circulating endothelial cells as biomarkers in clinical oncology. Microvascular Res 2010;79:224-8.

Zanardi A, Bandiera D, Bertolini F, Corsini C, Gregato G, Milani P, Barborini E, Carbone R. Miniaturized FISH for screening of onco-hematological malignancies. BioTechniques 2010; 49:497:504.

Perrotta S, Cucciolla V, Ferraro M, Ronzoni L, Tramontano A, Rossi F, Scudieri AC, Borriello A, Roberti D, Nobili B, Cappellini MD, Oliva A, Amendola G, Migliaccio AR, Mancuso P, Martin-Padura I, Bertolini F, Yoon D, Prchal JT, Della Ragione F. EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors. PLOS One 2010:pii e12015.

Martin-Padura I, Agliano A, Marighetti P, Porretti L, Bertolini F. Gender-related efficiency in NSG mice engraftment. Blood 2010:116:2616-7.

Mancuso P, Calleri A, Antoniotti P, Quarna J, Pruneri G, Bertolini F. If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. BMC Cancer 2010,10:644.

Bertolini F, Marighetti P, Shaked Y. Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate post-resistance therapy. Biochim Biophys Acta Reviews Cancer 2010;1806:131-7.

Bono A, Bianchi PP, Locatelli A, Calleri A, Quarna J, Antoniotti P, Rabascio C, Mancuso P, Andreoni B, Bertolini F. Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer. Cancer Biol Ther 2010;10:1-5.

Mancuso P, Martin-Padura I, Calleri A, Marighetti P, Quarna J, Braidotti P, Bertolini F. Circulating perivascular progenitors, a target of PDGFR inhibition. Int J Cancer, 2011;129:1344-50.

Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, Wickman GR, Chen JH, Wang J, X, Amundson K, Simon R, Erbersdobler A, Bergqvist S, Feng Z, Swanson T, Simmons BH, Lippincott J, Casperson GF, Levin WJ, Gallo Stampino C, Shalinsky DR, Ferrara KW, Fiedler W, Bertolini F. Targeting ALK1 kinase Inhibits Angiogenesis and Tumor Growth Through a Mechanism of Action Complementary to Anti-VEGF Therapies. Cancer Res, 2011;71:1362-73.

Fadini GP, de Kreutzenberg SV, Mariano V, Boscaro E, Bertolini F, Mancuso P, Quarna J, Marescotti M, Agostini C, Tiengo A, Avogaro A. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized cross-over trial comparing detemir versus glargine. Diabetes Obesity Metabolism 2011;13:718-25.

Belloni E, Shingh D, Tapinassi C, Viale A, Mancuso P, Marazzi O, Gerbino E, Dall’Olio V, Bertolini F, Pelicci PG. In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels. Leukemia, 2011;25:733-6.

Bertolini F, Mancuso P, Shaked Y. Circulating endothelial cells as biomarkers for patients receiving bevacizumab. The Lancet Oncol, 2011;12:217-8.

Bertolini F. Anti-angiogenesis in cancer, met and unmet goals. An interview with Robert Kerbel. Int J Dev Biol, 2011;55:395-8

A Berruti, D Generali, M.Kaufmann, L Pusztai, G Curigliano, M Aglietta, L Gianni, WR Miller, M Untch, C Sotiriou, MG Daidone, PF Conte, D Kennedy, G Damia, PG Petronini, S Di Cosimo, P Bruzzi, M.Dowsett, C Desmedt, R Mansel, S Marsoni, C Tondini, A Sapino, P Fenaroli, GP Tortora, H Thorne, RE Mansel, F Bertolini, F Ferrozzi, M Danova, E Tagliabue, E De Azambuja, A Makris, M Tampellini, G Dontu, L Van’t Veer, AL Harris, SB Fox, L Dogliotti, A Bottini. International expert consensus on primary systemic therapy in the management of early breast cancer. J Natl Cancer Inst Monograph 2011;43:147-51.

Bertolini F, Marighetti P, Martin-Padura I, Mancuso P, Hu-Lowe DD, Shaked Y, D’Onofrio A. Anti-VEGF and beyond: Shaping a new generation of anti-angiogenic therapies for cancer. Drug Discovery Today, 2011;16:1052-60.

Colombo F, Baldan F, Mazzucchelli S, Martin-Padura I, Marighetti P, Cattaneo A, Foglieni B, Spreafico M, Guerneri S, Baccarin M, Bertolini F, Rossi G, Mazzaferro V, Cadamuro M, Agnelli L, Rebulla P, Prati D, Porretti L. Evidence of distinct tumor-propagating cell populations with different properties in primary human hepatocellular carcinoma. PLOS One, 2011;6(6):e21369. Epub 2011 Jun 23.

Agliano A, Martin-Padura I, Marighetti P, Gregato G, Calleri A, Prior C, Redrado M, Calvo A, Bertolini F. Therapeutic effect of Lenalidomide in a novel xenograft mouse model of human Blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res, 2011;17:6163-73.

Gingis-Velitski S, Loven D, Benayoun L, Munster M, Bril R, Voloshin T, Alishekevitz D, Bertolini F, Shaked Y. Host response to chemotherapy induces matrix metalloproteinse-9 expression and accelerates metastasis in mice. Cancer Research 2011;71:6986-96.

Bertolini F. Response to anti-angiogenesis: An ever changing feature. Breast 2011;(S3); S61-2.

Martin-Padura I, Gregato G, Marighetti P, Mancuso P, Calleri A, Corsini C, Pruneri G, Manzotti M, Lohsiriwat V, Rietjens M, Petit JY, Bertolini F. The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression. Cancer Research 2012;72:325-34.

Petit JY, Botteri E, Lohsiriwat V, Curigliano G, Rietjens M, De Lorenzi F, Garusi C, Rosseto F, Martella S, Manconi A, Bertolini F, Veronesi P, Santillo B, Rotmensz N. Locoregional Recurrence Risk after Lipofilling in Breast Cancer Patients. Ann Oncol 2012;23:582-8.

Bertolini F, Lohsiriwat V, Petit JY, Kolonin MG. Adipose tissue cells, lipotransfer and cancer: An urgent challenge for scientists, oncologists and surgeons. BBA Reviews in Cancer 2012; 1826:209-14.

Bertolini F Anti-vascular endothelial growth factor treatment for eye disease (letter). Br Medical Journal 2012;344e:2970.

Martin-Padura I, Marighetti P, Agliano A, Porretti L, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F, Calvo A. Residual dormant cancer stem cell foci are responsible for tumor

relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest, 2012;92:952-66

Dellapasqua S, Bagnardi V, Bertolini F, Sandri MT, Pastrello D, Cancello G, Montagna E, Balduzzi A, Mancuso P, Luini A, Goldhirsch A, Colleoni M. Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast, 2012;21:209-13.

Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G, Viale G, Veronesi P, Luini A, Intra M, Calleri A, Rampinelli Cm Goldhirsch A, Bertolini F, Colleoni M. Metronomic chemotherapy combined with bevacizumab and erlotinib in metastatic HER2 negative breast cancer patients: clinical and biological activity. Clinical Breast Cancer, 2012;12:207-14.

Fadini GP, Mancuso P, Bertolini F, de Kreutzenberg S, Avogaro A Amelioration of glucose control mobilizes circulating pericyte progenitor cells in type 2 diabetic patients with microangiopathy. Exp Diabetes Res 2012; 2012:274363

Bertolini F. Lenalidomide in multiple myeloma (letter). New Engl J Med 2012;367:573-5.

Martin-Padura I, Agliano A, Gregato G, Marighetti M, Malazzi O, Mancuso P, Pruneri G

Viale A, Bertolini F. Spontaneous cell fusion of acute leukemia cells and macrophages observed in cells with leukemic potential. Neoplasia 2012;14:1057-66.

Pelosi E, Castelli G, Martin-Padura I,, Bordoni V, Santoro S, Conigliaro A, Cerio AM, De Santis Puzzonia M, Marighetti P, Biffoni M, Alonzi T, Amicone L, Alcalay M, Bertolini F, Testa U, Tripodi M. Human Haemato-endothelial Precursors: Cord blood CD34+ Cells Produce Haemogenic Endothelium. PloS ONE, 2012;7:e51109.

Loven D, Hasnis E, Bertolini F, Shaked Y. Low-dose metronomic chemotherapy: From from past experiences to new paradigms in the treatment for cancer. Drug Discovery Today, 2013:18:193-201.

Bertolini F, Shaked Y, Mancuso P. On the clinical relevance of circulating endothelial cells and platelets in prostate cancer (letter). Br J Cancer 2013;108;1387.

Petit JY, Rietjens M, Botteri E, Rotmensz N, Bertolini F, Curigliano G, Rey P, Garusi C, De Lorenzi F, Martella S, Manconi A, Barbieri B, Veronesi P, Intra M, Brambullo T, Gottardi A, Sommario M, Lomeo G, Iera M, Giovinazzo V, Lohsiriwat V. Evaluation of fat grafting safety in patients with intra epithelial neoplasia: a matched-cohort study. Ann Oncol, 2013;24:1479-


Bertolini F. Adipose tissue and breast cancer progression: A link between metabolism and cancer. The Breast 2013;22 (Suppl1): S6-7.

Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, Pellegatta S, Mancuso P, Porrati P, Di Stefano AL, Ceroni M, Bertolini F, Finocchiaro G, Eoli M. Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One. 2013;8:e74345.

Bertolini F. Contribution of endothelial precursors of adipose tissue to breast cancer: progression-link with fat graft for reconstructive surgery. Ann Endocrinol (Paris). 2013;74:106-7.

Orecchioni S, Gregato G, Martin-Padura I, Reggiani F, Braidotti P, Mancuso P, Calleri A, Quarna J, Marighetti P, Aldeni C, Pruneri G, Martella S, Manconi A, Petit JY, Rietjens M, Bertolini F. Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer. Cancer Res 2013;73:5880-91.

Dallaglio K, Bruno A, Cantelmo AR, Esposito AI, Ruggiero L, Orecchioni S, Calleri A, Bertolini F, Pfeiffer U, Noonan DM, Albini A. Paradoxic effects of Metformin on endothelial cells and angiogenesis. Carcinogenesis 2014;35:1055-66.

Bertolini F, Mancuso P, Heymach JV. About CD45-/CD31+/CD105+ circulating cells in patients with gynecologic malignancies. Clinical Cancer Res 2014;20:1393.

Gelao L, Bagnardi V, Locatelli MA, Bertolini F, Criscitiello C, Esposito A, Viale G, Alkalay M, Goldhirsch A, Curigliano G. 36p * gene expression analysis of triple negative recurrent lymphangitic breast cancer in patients receiving antiangiogenic therapy. Ann Oncol. 2014 May;25 Suppl 1:i12.

Mancuso P, Calleri A, Gregato G, Labanca V, QuarnaJ, Antoniotti P, Cuppini L, Finocchiaro G, Eoli M, Rosti V, Bertolini F. A subpopulation of circulating endothelial cells express CD109 and is enriched in the blood of cancer patients. PLoS One 2014, DOI: 0.1371/journal.pone.0114713

Bertolini F, Orecchioni S, Petit JY, Kolonin MG. Obesity, proinflammatory mediators, adipose tissue progenitors and breast cancer. (Review). Curr Opin Oncol, 2014;26:545-50.

Bertolini F, Petit JY, Kolonin MG. Stem cells from the adipose tissue and breast cancer: Hype, risks, and hope (Review). Br J Cancer, 2015, 112(3):419-23. doi: 10.1038/bjc.2014.657. Epub 2015 Jan 13.

Orecchioni S, Reggiani F, Talarico G, Mancuso P, Calleri A, Gregato G, Labanca V, Noonan DM, Dallaglio K, Albini A, Bertolini F. The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. Int J Cancer, 2015 Mar 15;136(6):E534-44. doi: 10.1002/ijc.29193. Epub 2014 Sep 18.

Curigliano G, Bagnardi V, Bertolini F, Alcalay M, Locatelli MA, Fumagalli L, Rabascio C, Calleri A, Adamoli L, Criscitiello C, Viale G, Goldhirsch A.. Antiangiogenic therapy in recurrent inflammatory breast cancer with lymphangitic spread to the chest wall: A randomized phase II

trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. The Breast, 2105; 24:263-71.

Belloni E, Martin-Padura I, Gerbino E, Orecchioni S, Fusar Imperatore F, Marighetti P; Bertalot G, Pelicci PG, Bertolini F. Lung cancer onset in wild type mice following bone marrow reconstitution with k.rasv12 cells. Scientific Reports 2015;5:13047. doi: 10.1038/srep13047.

Falzacappa MV, Ronchini C, Faretta M, Iacobucci I, Ghelli A, Martinelli G, Meyer LH, Debatin KM, Orecchioni S, Bertolini F, Pelicci PG. The combination of the PARP inhibitor rucaparib and 5FU i san effective strategy for treating acute leukemia. Mol Cancer Ther, 2015;14:889-98.

Allende-Vega N, Krzywinska E, Orecchioni S, Lopez-Royuela N, Reggiani F, Talarico G, Rossi JF, Rossignol R, Hicheri Y, Cartron G, Bertolini F, Villalba M. The efficacy of combinational therapy targeting metabolism in hematological cancers is dependent on the p53 tumor suppressor status. Oncotarget 2015;6:19228-45.

Petit JY, Maisonneuve P, Rotmensz N, Bertolini F, Clough KB, Sarfati I, Gale KL, Macmillan RD, Rey P, Benyahi D, Rietjens M. Safety of lipofilling in patients with breast cancer. Clin Plast Surg, 2015;42:339-44.

Orecchioni S, Reggiani F, Talarico G, Bertolini F. Mechanisms of obesity in the development of breast cancer. Discovery Medicine 2015;20:121-8

Bertolini F, Sukhatme VP, Bouche G. Drug repurposing in oncology—patient and health systems opportunities. Nature Reviews Clin Oncol 2015,12:732-742.

Gruszka A, Rabascio C , Cannella L, Sammassimo S, Andreola G , Gregato G, Calleri A, De Molfetta R, Pruneri G, Bertolini F, Alcalay M. Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma. Scientific Reports 2015;5:14829. Doi 10.1038/srep14829

Allegretti A, Ricciard MR, Licchetta R, Mirabili S, Orecchioni S, Reggiani F, Talarico G, Roa R, Bertolini F, Amadori S, Torrisi MR, Tafuri A. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. Scientific Reports 2015,5:18137. Doi:10.1038/srep181372015.

Khan A, et al (Bertolini F, Villalba M). Human leukemic cells performing oxidative phosphorylation (OXPHOS) generate an antioxidant response independently of reactive oxygen species (ROS) production. E-BioMedicine 2015;3:43-53

Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, Gregato G, Labanca V, Rossi T, Noonan DM, Albini A, Bertolini F. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Scientific Reports, 2016; 6:18673. Doi: 10.1038/srep18673.

Goff LW, Cohen RB, Berlin JD, deBraud F, Lyschick A, Noberasco C, Bertolini F, Carpentieri M, Gallo-Stampino C, Abbattista A, Wang E, Borghaei H. A Phase 1 Study of the Anti-Activin

Receptor-Like Kinase 1 (ALK-1) Antibody PF-03446962 in Patients With Advanced Solid Tumors. Clin Cancer Res 2016;22:2146-54.

Labanca V, Bertolini F. A combinatorial investigation of the response to anti-angiogenic therapy in breast cancer: new strategies for patient selection and opportunities for reconsidering anti-VEGF, anti-PI3K and checkpoint inhibition. E-Biomedicine 2016 pp. 13-14 DOI information: 10.1016/j.ebiom.2016.07.038

Salvestrini V, Orecchioni S, Talarico G, Reggiani F, Mazzetti C, Bertolini F, Orioli E, Adinolfi E, Di Virgilio F, Pezzi A, Cavo M, Lemoli RM, Curti A. Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. Oncotarget 2017 Jan 24;8(4):5895-5908. doi: 10.18632/oncotarget.13927.

Rachman-Tzemah C, Zaffryar-Eilot S, Grossman M, Ribero D, Timaner M, Mäki JM, Myllyharju J, Bertolini F, Sagi I, Hasson P, Shaked Y. Blocking surgically-induced lysyl oxidase activity reduces risk of lung metastases. Cell Reports. 2017;19:774-784. doi: 10.1016/j.celrep.2017.04.005.

Reggiani F, Labanca V, Mancuso P, Rabascio C, Talarico G, Orecchioni S, Manconi A, Bertolini F. Adipose progenitor cell secretion of GM-CSF and MMP9 promotes a stromal and immunological microenvironment that supports breast cancer progression. Cancer Res. 2017;77:5169-82. doi: 10.1158/0008-5472.CAN-17-0914.

Petit JY, Maisonneuve P, Rotmensz N, Bertolini F, Rietjens M. Fat Grafting after Invasive Breast Cancer: A Matched Case-Control Study. Plast Reconstr Surg. 2017 Jun;139(6):1292-1296. doi: 10.1097/PRS.0000000000003339.

Khan AUH, Allende-Vega N, Gitenay D, Gerbal-Chaloin S, Gondeau C, Vo DN, Belkahla S, Orecchioni S, Talarico G, Bertolini F, Bozic M, Valdivielso JM, Bejjani F, Jariel I, Lopez-Mejia IC, Fajas L, Lecellier CH, Hernandez J, Daujat M, Villalba M.The PDK1 Inhibitor Dichloroacetate Controls Cholesterol Homeostasis Through the ERK5/MEF2 Pathway. Sci Rep, 2017 Sep 6;7(1):10654. doi: 10.1038/s41598-017-10339-5.

Reggiani F, Bertolini F. GM-CSF promotes a supportive adipose and lung microenvironment in metastatic breast cancer. Oncoscience 2017;4:126-7.

Reggiani F, Bertolini F. Roles of obesity in the development and

progression of breast cancer. Discovery Medicine 2017;24:183-


Cagnetta A, Soncini D, Orecchioni S, Talarico G, Minetto P, Guolo F, Retali V, Colombo N, Carminati E, Clavio M, Miglino M, Bergamaschi M, Nahimana A, Duchosal M, Todoerti K, Neri A, Passalacqua M, Bruzzone S, Nencioni A, Bertolini F, Gobbi M, Lemoli RM, Cea M. Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents. Haematologica. 2018;103:80-90.7; pii: haematol.2017.176248. doi: 10.3324/haematol.2017.176248.

Zuccolo E, Di Buduo C, Lodola F, Orecchioni S, Scarpellino G, Kheder DA, Poletto V, Guerra G, Bertolini F, Balduini A, Rosti V, Moccia F. Stromal cell-derived factor-1α promotes endothelial colony forming cell migration through the Ca2+-dependent activation of the extracellular signal-regulated kinase 1/2 and phosphoinositide 3-kinase/AKT pathways. Stem cells and development 2018;27:23-34.

Sanarico AG, Ronchini C, Croce A, Memmi EM, Cammarata UA, De Antoni A, Lavorgna S, Divona M, Giacò L, Melloni G, Brendolan A, Mancuso P, Bertolini F, Lo-Coco F, Melino G, Pelicci PG, Bernassola F.The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia. Leukemia 2018;32:911-919. doi: 10.1038/leu.2017.342.

Sanchez D, Allende-Vega N, Orecchioni S, Talarico G, Cornillon A, Vo D, Rene C, Lu Z, Krzywinska E, Anel A, Galvez EM, Pardo J, Robert B, Martineau P, Hicheri Y, Bertolini F, Cartron G, Villalba M. Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumor cells. Theranostics 2018; 8(14):3856-3869. doi:10.7150/thno.25149.

Belkahla S, Haq Khan AU, Gitenay D, Alexia C, Gondeau C, Vo DN, Orecchioni S, Talarico G, Bertolini F, Cartron G, Hernandez J, Daujat-Chavenieu M, Allende-Vega N, Gonzalez MV. Changes in metabolism affect expression of ABC Transporters Through ERK5 and Depending on p53 status. Oncotarget 2017;9:1114-1129. doi: 10.18632/oncotarget.23305. eCollection 2018 Jan 2.

Orecchioni S, Talarico G, Labanca V, Mancuso P, Calleri A, Bertolini F. Vinorelbine, cyclophosphamide, and 5-FU effects on the circulating and intratumoral landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. Br J Cancer 2018;118:1329-1336. doi: 10.1038/s41416-018-0076-z.

Khan AUH, Allende-Vega N, Gitenay D, Garaude J, Vo DN, Belkhala S, Gerbal-Chaloin S, Gondeau C, Daujat-Chavanieu M, Delettre C, Orecchioni S, Talarico G, Bertolini F, Anel A, Cuezva JM, Enriquez JA, Cartron G, Lecellier CH, Hernandez J, Villalba M. Mitochondrial Complex I activity signals antioxidant response through ERK5. Sci Rep. 2018;8:7420. doi: 10.1038/s41598-018-23884-4.

Sapienza MR, Abate F, Melle F, Orecchioni S, Fuligni F, Etebari M, Tabanelli V, Laginestra MA, Pileri A, Motta G, Rossi M, Agostinelli C, Sabattini E, Pimpinelli N, Truni M, Falini B, Cerroni L, Talarico G, Piccioni R, Amente S, Indio V, Tarantino G, Brundu F, Paulli M, Berti E, Facchetti F, Dellino GI, Bertolini F, Tripodo C, Rabadan R, Pileri SA. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica 2019;104:729-37.

Bertolini F. Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors (Editorial). Br J Cancer 2019;120:139-40.

Orecchioni S, Roma S, Raimondi S, Gandini S, Bertolini F. Identifying drug repurposing in oncology. Cancer J, 2019;25:82-87.

Passaro A, Mancuso P, Gandini S, Spitaleri G, Labanca V, Guerini-Rocco E, Barberis M, Catania C, Del Signore E, de Marinis F, Bertolini F. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy. Clin Transl Oncol. 2020;22:603-11.

Abdel-Aziz AK, Saadeldin MK, D'Amico P, Orecchioni S, Bertolini F, Curigliano G, Minucci S. Preclinical Models Of Breast Cancer: Two-Way Shuttles For Immune Checkpoint Inhibitors From And To Patient Bedside. Eur J Cancer 2019, 2019 Oct 10;122:22-41. doi: 10.1016/j.ejca.2019.08.013.

Soncini D, Orecchioni S, Ruberti S, Minetto P, Martinuzzi C, Agnelli L, Todoerti K, Cagnetta A, Miglino M, Clavio M, Contini P, Varaldo R, Bergamaschi M, Guolo F, Passalacqua M, Nencioni A, Monacelli F, Gobbi M, Neri A, Abbadessa G, Eathiraj S, Schwartz B, Bertolini F, Lemoli RM, Cea M. The novel small BTK inhibitor ARQ 531 targets acute myeloid leukemia cells by disrupting tumor-addicted transcriptional programs. Haematologica 2020;105:2420-31.

Todisco E, Gigli F, Sammassimo S, Camisaschi C, Mancuso P, Ronchini C, Ramadan S, Bertolini F, Pastano R, Tarella C. Efficacy of venetoclax based salvage chemotherapy followed by "Minimal Residual Disease driven"-venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia. Leuk Lymphoma. 2020 May 2:1-3. doi: 10.1080/10428194.2020.1759049.

Salvestrini V, Ciciarello M, Pensato V, Simonetti G, Laginestra MA, Bruno S, Pazzaglia M, De Marchi E, Forte D, Orecchioni S, Martinelli G, Bertolini F, Méndez-Ferrer S, Adinolfi E, Di Virgilio F, Cavo M, Curti A. Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells. Front Oncol. 2020 Jul 24;10:1225. doi: 10.3389/fonc.2020.01225.

Falvo P, Orecchioni S, Roma S, Raveane A, Bertolini F. Drug repurposing in Oncology, an attractive opportunity for novel combinatorial regimens. Curr Med Chem 2020;27:1-23.

Laszlo D, Marcacci GP, Martino M, Radice D, Caime A, Menna S, Lionetti MT, Bertolini F. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis. Transf Apheresis Sci, 2020; 52:102819.

Berzuini A, Bianco C, Bertolini F, Gregato G, Cattaneo A, Erba E, Bandera A, Gori A, Lamorte G, Manunta M, Porretti L, Revelli N, Truglio F, Grasselli G, Zanella A, Villa S, Valenti L, Prati D. Red cell bound antibodies and transfusion requirements in hospitalized patients with COVID-19. Blood 2020;136:766-8.

Mutti G, Raveane A, Pagano A, Bertolini F, Semino O, Balestrazzi A, Macovei A. Plant TDP1 (tyrosyl-DNA phosphodiesterase 1) after 10 years of research: a phylogenetic perspective and gene expression data mining. Genes, 2020;11:1465. doi: 10.3390/genes11121465.

Mancuso P, Gidaro A, Gregato G, Raveane A, Cremonesi P, Quarna J, Caccia S, Gusso L, Rusconi S, Giacomelli A, Cogliati C, Bertolini F. Circulating endothelial progenitors are increased in Covid-19 patients and correlate with SARS-CoV-2 RNA in severe cases. J Thromb Haemost 2020; 10.1111/jth.15044. doi: 10.1111/jth.15044.

Todisco E, Ronchini C, Bertolini F, Tarella C. Clinical presentation, diagnosis and management of Therapy-Related Hematological Disorders in Women with Epithelial Ovarian Cancer treated with Chemotherapy and Poly-ADP-Ribose Polymerase Inhibitors (PARP-i): a single Center experience. Int J Cancer 2021;148:170-7.

Falvo P, Orecchioni S, Hillje R, Raveane A, Mancuso P, Camisaschi C, Luzi L, Pelicci PG, Bertolini F. Cyclophosphamide and vinorelbine activate stem-like CD8+ T cells and improve anti-PD-1 efficacy in triple-negative breast cancer. Cancer Res 2021;81:685–97.

Capodiferro MR, Aram B, Raveane A, Rambaldi Migliore N, Colombo G, Ongaro L, Rivera J, Mendizábal T, Hernández-Mora I, Tribaldos M, Perego UA, Li H, Scheib CL, Modi A, Gòmez-Carballa A, Grugni V, Lombardo G, Hellenthal G, Pascale JM, Bertolini F, Grieco G, Cereda C, Lari M, Caramelli D, Pagani L, Metspalu M, Friedrich R, Knipper C, Olivieri A, Salas A, Cooke R, Montinaro F, Motta J, Torroni A, Martín JG, Semino O, Malhi RS, Achilli A. Archaeogenomic Distinctiveness of the Isthmo-Colombian Area. Cell 2021; 184: 1706-23.

Reggiani F, Falvo P, Bertolini F. Cellular and molecular players in the interplay between adipose tissue and cancer cells. Int J Mol Sci 2021;22:1359-79.

Falvo P, Orecchioni S, Raveane A, Mitola G, Bertolini F. A “two-hit”, (chemo)therapy to improve checkpoint inhibition in cancer (Editorial). Oncoscience 2021;8:55-57.

Roma S, Raveane A, Carpen L, Bertolini F. The dual role of innate lymphoid and natural killer cells in cancer. From phenotype to single-cell transcriptomics, function and clinical use (Review). Cancers 2021;13:5042

Mitola G, Falvo P, Bertolini F. New insight to overcome tumor resistance: Molecular and cellular mechanisms (review). Life 2021,11:1131.

Barosi G, Rosti V, Massa M, Campanelli R, Villani L, Catarsi P, Carolei A, Abbà C, Lodigiani C, Primignani M, Gregato G, Bertolini F, Magrini U, Gale RP. Clonal megakaryocyte dysplasia with normal blood values is a distinct myeloproliferative neoplasm. Acta Haematol 2022;145:30-7.

Rossi A, Orecchioni S, Falvo P, Tabanelli V, Baiardi E, Agostinelli C, Melle F, Motta G, Calleri A, Fiori S, Corsini C, Casadei B, Mazzara S, Vitolo U, Bertolini F, Zinzani PL, Alcalay M, Pelicci PG, Pileri S, Tarella C, Derenzini E. Dual targeting of the DNA Damage Response Pathway and BCL-2 in Diffuse Large B-cell Lymphoma. Leukemia 2022;36:197-209.

Allende-Vega N, Brualla JM, Falvo P, Alexia C, Constantinides M, Herbe-de-Maudave AF, Coenon L, Gitenay D, Mitola G, Massa P, Orecchioni S, Bertolini F, Marzo I, Anel A, Villalba M. Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). Sci Rep, 2022, 12:1341.

Carpen L, Falvo P, Orecchioni S, Mitola G, Hilje R, Mazzara S, Mancuso P, Pileri S, Raveane A, Bertolini F. A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies. Cell Death Discovery 2022;8:106

Belkahla S, Brualla JM, Fayd'herbe de Maudave A, Falvo P, Allende-Vega N, Constantinides M, Khan AUH, Coenon L, Alexia C, Mitola G, Massa P, Orecchioni S, Bertolini F, Mnif W, Hernandez J, Anel A, Villalba M. The Metabolism of tumor cells regulates their sensitivity to NK cells depending on p53 status. Sci Rep 2022;12:3234.

Raveane A, Molinaro L, Aneli S, Capodiferro MR, de Gennaro L, Ongaro L, Rambaldi Migliore N, Soffiati S, Scarano T, Torroni A, Achilli A, Ventura M, Pagani L, Capelli C, Olivieri A, Bertolini F, Semino O, Montinaro F. Assessing temporal and geographic contacts across the Adriatic Sea through the analysis of genome-wide data from Southern Italy. Genomics 2022;114:110405. doi: 10.1016/j.ygeno.2022.110405.

Todisco E, Gigli F, Ronchini C, Amato V, Sammassimo S, Pastano R, Parma G, Lapresa MT, Bertolini F, Corsini C, Gregato G, Poletti C, Pelicci PG, Alcalay M, Colombo N, Tarella C. Hematological disorders after salvage PARPIs for ovarian cancer: cytogenetic and molecular defects and clincal outcomes. Int J Cancer 2022;151:1791-803.

Cortellino S, Raveane A, Chiodoni C, Delfanti G, Pisati F, Visco E, Spagnolo V, Fregale G, Ferrante F, Rotta L, Riboni M, Martini M, Magni S, Martone L, Iannelli F, Zanardi F, Casorati G, Bertolini F, Dellabona P, Colombo MP, Tripodo C, Longo DV. Fasting modulates breast tumour microenvironment and enhances immunotherapy. Cell Reports 2022;40:111256, online ahead of print.

Cella CA, Spada F, Berruti A, Bertolini F, Mancuso P, Barberis M, Pisa E, Rubino M, Gervaso L, Laffi A, Pellicori S, Radice D, Zorzino L, Calleri A, Funicelli L, Petralia G, Fazio N. Addressing the role of angiogenesis in patients with advanced pancreatic neuroendocrine tumors treated with everolimus: a biological prospective analysis of soluble biomarkers and clinical outcomes. Cancers 2022;14:4471. doi: 10.3390/cancers14184471.

Roma S, Camisaschi C, Mancuso P, Trabanelli S, Vanazzi A, Villa S, Prati D, Fiori S, Lorenzini D, Tabanelli V, Pileri S, Tarella C, Jandus C, Bertolini F. Dampening of cytotoxic Innate lymphoid Cells: a new tumour immune escape mechanism in B cell non-Hodgkin's lymphoma. Cellular Immunology 2022;382:104615. doi: 10.1016/j.cellimm.2022.104615.

Barosi G, Campanelli R, Massa M, Catarsi P, Carolei A, Abba C, Villani L, Magrini U, Gregato G, Bertolini F, de Silvestri A, Gale R, Rosti V. Clonal megakaryocyte dysplasia with isolated thrombocytosis (CMD-IT) is a distinct myeloproliferative neoplasm phenotype. Acta Haematol 2023;146:14-25.

Orecchioni S, Falvo P, Talarico G, Mitola G, Bravetti G, Mancuso P, Nicoli P, Bertolini F. Vinorelbine and intermittent cyclophosphamide sensitize an aggressive Myc-driven B-cell lymphoma to anti-PD-1 by an immunological memory effective against tumor re-challenge. J Clin Med, 2023;12:2535.

Bravetti G, Falvo P, Talarico G, Orecchioni S, Bertolini F. Metronomic chemotherapy, dampening of immunosuppressive cells, antigen presenting cell activation, and T cells. A quartet against refractoriness and resistance to checkpoint inhibitors. Cancer Letters 2023

Pensato V, Laginestra MA, Falvo P, Orecchioni S, Talarico G, De Marchi E, Bruno S, Mongiorgi S, Mitola G, Bertolini F, Adinolfi E, Cavo M, Curti A, Salvestrini V. The bitter taste receptor agonist denatonium inhibits stemness characteristics in hematopoietic stem cells. Stem Cells 2024;42:42-54.

Mazzarella L, Falvo P, Adinolfi M, Tini G, Gatti E, Piccioni R, Bonetti E, Gavilan Dorronzoro E, Valli D, Gruszka A , Bodini M, Gallo B , Orecchioni S , Achutti Duso B, Roerink S , Stratton M , Bertolini F , Alcalay M , Dellino GI, Pelicci PG. High-fat diet promotes acute promyelocytic leukemia through PPARδ enhanced self-renewal of preleukemic progenitors. Cancer Prev Res, 2023 Nov 13. doi: 10.1158/1940-6207.CAPR-23-0246.

Reggiani F, Talarico G, Gobbi G, Sauta E, Torricelli F, Manicardi V, Zanetti E, Orecchioni S, Falvo P, Piana S, Lococo F, Paci M, Bertolini F, Ciarrocchi A, Sancisi V. BET inhibitors drive natural killer cell activation in non-small cell lung cancer via BRD4 and SMAD3. Nature Comm, in press.

Gervaso L, Ciardiello D, Gregato G, Guidi L, Valenza C, Ascione L, Boldrini L, Frassoni S, Cella C, Spada F, Funicelli L, De Roberto G, Pet WL, Borin S, Gerardi M, Bottiglieri L, Tamayo D, Fumagalli Romario U, Bagnardi V, Curigliano G, Bertolini F, Fazio N; Zampino MG. Circulating tumor DNA in patients with locally advanced rectal cancer treated with multimodal treatment. Submitted, 2024.

Avenoso A, Squillario M, Barla A, Verri A, Carminati E, Nurra C, Todisco E, Gigli F, Bertolini F, Gregato G, Poletti C, Miglino M. Epigenetic Regulation in Myelodysplastic Syndrome as A Consequence of A MicroRNA Dysregulation, A Different Perspective with integration For Comprehension Of Pathogenesis And Disease Progression. Submitted

Chiara Ronchini1, Federica Gigli2, Martina Fontanini1, Raffaella Furgi1, Viviana Amato2, Fabio Giglio2, Giuliana Gregato3, Francesco Bertolini3, Michela Rondoni4, Francesco Lanza4, Atto Billio5, Enrico Derenzini2,6, Corrado Tarella2,6, Pier Giuseppe Pelicci7,8, Myriam Alcalay7,8*, Elisabetta Todisco2,9* IDENTIFICATION OF NOVEL POTENTIAL PREDISPOSING VARIANTS IN FAMILIAL ACUTE MYELOID LEUKEMIA. Submitted

Falvo P, Gruener S, Pisati F, Orecchioni S, Talarico G, Mitola G. Bravetti G, Barozzi I, Bertolini F. Age-Dependent Differences in Breast Tumor Microenvironment: Challenges and Opportunities for Efficacy Studies in Preclinical Models. Submitted

Franceschini A, Raveane A, Falvo P, Mazzara S, Melle F, Motta G, Orecchioni S, Tenore A, Gregato G, Poletti C, Chiarle R, Pileri S, Mancuso P, Bertolini F. HSP and IFIT genes are over-expressed in symptomatic T- LGLL. Submitted.

  • The first author and FB equally contributed to the work.